Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Development of Protective Immunity in New Zealand White Rabbits Challenged with Bacillus anthracis Spores and Treated with Antibiotics and Obiltoxaximab, a Monoclonal Antibody against Protective Antigen.

Henning LN, Carpenter S, Stark GV, Serbina NV.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01590-17. doi: 10.1128/AAC.01590-17. Print 2018 Feb.

2.

Animal-to-Human Dose Translation of Obiltoxaximab for Treatment of Inhalational Anthrax Under the US FDA Animal Rule.

Nagy CF, Mondick J, Serbina N, Casey LS, Carpenter SE, French J, Guttendorf R.

Clin Transl Sci. 2017 Jan;10(1):12-19. doi: 10.1111/cts.12433. Epub 2016 Dec 7.

3.

Efficacy Projection of Obiltoxaximab for Treatment of Inhalational Anthrax across a Range of Disease Severity.

Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, O'Connor E, Gonzales N, Mondick J, French J, Stark GV, Fisher AC, Casey LS, Serbina NV.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5787-95. doi: 10.1128/AAC.00972-16. Print 2016 Oct.

4.

Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.

Yamamoto BJ, Shadiack AM, Carpenter S, Sanford D, Henning LN, Gonzales N, O'Connor E, Casey LS, Serbina NV.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5796-805. doi: 10.1128/AAC.01102-16. Print 2016 Oct.

5.

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.

Mohamed N, Clagett M, Li J, Jones S, Pincus S, D'Alia G, Nardone L, Babin M, Spitalny G, Casey L.

Infect Immun. 2005 Feb;73(2):795-802.

6.

Supplemental Content

Loading ...
Support Center